Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRM423 (BRIM Biotechnology, Inc.)
- Development stage
- Preclinical
- Lead developer
- BRIM Biotechnology
- Modality
- Peptides
- Administration
- Ophthalmic
01
Overview
BRM423 is a novel synthetic peptide being developed by BRIM Biotechnology (also known as Brim Healthcare) for the treatment of severe corneal damage. Derived from human Pigment Epithelium-Derived Factor (PEDF) using the company's proprietary Pigment Epithelium-Derived Factor-derived Short Peptide (PDSP) technology platform, BRM423 acts as a neurotrophic factor that stimulates corneal wound healing and repair. Preclinical studies have demonstrated its ability to promote the growth, expansion, and regeneration of limbal stem cells (LSCs), leading to superior and rapid corneal healing efficacy compared to standard treatments.
Beyond the preview
Go deeper on BRM423 (BRIM Biotechnology, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRM423 (BRIM Biotechnology, Inc.).